Welcome to our dedicated page for NeuroOne Medical Technologies Corporation news (Ticker: NMTC), a resource for investors and traders seeking the latest updates and insights on NeuroOne Medical Technologies Corporation stock.
NeuroOne Medical Technologies Corporation (symbol: NMTC) is a cutting-edge medical technology company based in Eden Prairie, Minnesota. The company specializes in the development and commercialization of innovative thin-film electrode technology designed for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, brain stimulation, and ablation solutions. These technologies are particularly beneficial for patients suffering from a variety of brain-related disorders, including epilepsy, Parkinson's disease, dystonia, and essential tremors.
NeuroOne's core business revolves around creating comprehensive neuromodulation solutions that integrate cEEG and sEEG recording, monitoring, brain stimulation, and ablation. This focus has led to notable advancements such as the Evo® sEEG system, which is the first FDA-cleared thin-film sEEG-guided RF system capable of both recording electrical activity and ablating nervous tissue, with the added benefit of temperature control.
The company is actively involved in various exciting projects and partnerships. One of their key initiatives is the Drug Delivery Program, which is expected to achieve several important milestones in the near future. Additionally, NeuroOne is continuously enhancing its product portfolio to better serve its target patient population.
Financially, NeuroOne has provided promising updates for the second quarter of the fiscal year 2024. The company’s recent business highlights include significant progress in their OneRF™ Ablation System and Spinal Cord Stimulation Program. Investors and interested parties can access more detailed financial results and updates through their quarterly conference calls and webcasts.
For more information or to get in touch with NeuroOne, please contact them at 800-631-4030 or email ir@nmtc1.com.
NeuroOne Medical Technologies (Nasdaq: NMTC) has regained compliance with Nasdaq Capital Market's continued listing requirements for minimum share price under Rule 5550(a)(2). The company received confirmation from Nasdaq's Listings Qualifications Hearing Department on February 3, 2025, resulting in the cancellation of a previously scheduled hearing.
The company also reported preliminary unaudited first quarter fiscal 2025 total revenue of $6.2 million, comprising $3.2 million in product revenue and a one-time $3.0 million license revenue payment. NeuroOne's CEO Dave Rosa highlighted the company's focus on their OneRF Ablation System, which is the first and only FDA-cleared device for RF ablation in the brain. The company will provide further updates during their upcoming earnings call scheduled for February 12, 2025, at 8:30 am eastern time.
NeuroOne Medical Technologies (NASDAQ: NMTC) announced preliminary unaudited revenue for Q1 fiscal 2025 (ended December 31, 2024) of $6.2 million, a significant increase from $1.0 million in Q1 fiscal 2024. This includes a one-time $3.0 million collaboration payment from Zimmer Biomet for the OneRF™ Ablation System commercialization agreement, plus $3.2 million in product revenue, representing a 227% increase year-over-year.
The company reiterated its fiscal 2025 product revenue guidance (excluding collaboration revenue) of $8.0-$10.0 million, with expected product gross margins between 47-51%. The Zimmer Biomet agreement includes potential additional milestone payments based on performance criteria. Complete financial results for the quarter are expected in February 2025.
NeuroOne Medical Technologies (NMTC) has rescheduled its Virtual Investor Webinar to Friday, January 10, 2025, due to U.S. markets closure for former President Jimmy Carter's National Day of Mourning. During the webinar, CEO Dave Rosa will present the company's business model and recent achievements, including their expanded exclusive distribution agreement with Zimmer Biomet.
The company reported significant financial growth with product revenue increasing 77% to $3.5 million in fiscal year 2024. For fiscal year 2025, NeuroOne projects product revenue between $8 and $10 million, representing a substantial growth of 132% to 190%. The presentation will be followed by a Q&A session, accessible via webcast or dial-in, with playback available through January 24, 2025.
NeuroOne Medical Technologies (NASDAQ: NMTC) announced a virtual investor webinar scheduled for January 9, 2025, at 11:00 a.m. EST. CEO Dave Rosa will present the company's business model and recent achievements, including their expanded exclusive distribution agreement with Zimmer Biomet.
The company reported significant financial growth with product revenue increasing 77% to $3.5 million in fiscal year 2024. For fiscal year 2025, NeuroOne projects product revenue between $8 and $10 million, representing a growth of 132% to 190%.
The webinar will include a presentation and Q&A session, with both U.S. and international dial-in options available. A playback will be accessible through January 23, 2025.
NeuroOne Medical Technologies (NMTC) reported significant growth in fiscal 2024, with product revenue increasing 77% to $3.5 million. The company expanded its exclusive distribution agreement with Zimmer Biomet, receiving a $3 million upfront payment in November 2024. For fiscal 2025, NeuroOne projects product revenue between $8-10 million, representing 132-190% growth, with expected gross margins of 47-51%, up from 31% in 2024.
The OneRF™ Ablation System has been implemented in 5 prominent epilepsy centers, with successful procedures on 12 patients. Operating expenses decreased 12% to $3.0 million in Q4 2024. The company remains debt-free, though cash position decreased to $1.5 million as of September 30, 2024, compared to $5.3 million the previous year.
NeuroOne Medical Technologies (NASDAQ: NMTC), a medical technology company focused on improving surgical care options for neurological disorders, has scheduled its fourth quarter and fiscal year 2024 financial results release for December 17, 2024, before market open. The company will host an investor conference call and webcast at 9:00 a.m. Eastern time on the same day, featuring management discussion, corporate updates, and a Q&A session.
The earnings call will be accessible via U.S. toll-free (888-506-0062) and international (973-528-0011) dial-in numbers, with participant access code 603219. A playback will be available through December 31, 2024, and a webcast replay will be accessible until December 17, 2025.
NeuroOne Medical Technologies (Nasdaq: NMTC), a medical technology company specializing in neurological disorder treatments, has announced its participation in the upcoming Virtual Investor Summit Microcap Event on November 21, 2024. The company will deliver a presentation from 1:30 PM to 2:00 PM ET and will be available for one-on-one meetings throughout the day.
The event will showcase 40 micro-cap companies with catalysts and/or strong market performance. Interested qualified investors can register for complimentary access to participate in live Q&A sessions and engage with leading MicroCap investors.
NeuroOne Medical Technologies (NASDAQ: NMTC) has expanded its distribution agreement with Zimmer Biomet for the OneRF™ Ablation System. The amendment grants Zimmer Biomet exclusive rights to distribute the system for brain use. NeuroOne will receive a $3 million upfront payment with potential additional milestone payments. The OneRF system is the only FDA-cleared radiofrequency ablation system in the US for both diagnostic and therapeutic use, having demonstrated success in identifying and ablating brain tissue causing seizures. The system allows for bedside procedures, reducing hospital stays and operating costs while enabling diagnosis and treatment in a single hospitalization.
NeuroOne Medical Technologies (Nasdaq: NMTC), a medical technology company specializing in neurological disorder treatments, has announced its participation in The ThinkEquity Conference on October 30, 2024. The event will be held at the Mandarin Oriental Hotel in New York. CFO Ron McClurg will deliver a presentation at 9:00 am ET, and the company will conduct one-on-one investor meetings throughout the day. The conference brings together institutional investors, corporate clients, and industry professionals to showcase innovations and financial strategies. The presentation will be available via live stream, and interested investors can register to attend and schedule meetings.
NeuroOne Medical Technologies (Nasdaq: NMTC) announced that its percutaneous paddle technology for spinal cord stimulation will be featured at The Business of Pain Meeting in Nashville, TN. Dr. Sean Li, a renowned pain specialist and course director, will present on this innovative tool for lower back pain.
Dr. Li, President of the New Jersey Society of Interventional Pain Physicians and Treasurer of the American Society of Pain and Neuroscience, praised the technology as the most advanced percutaneous spinal cord stimulation electrode he has worked with. He believes it combines the benefits of surgically placed paddle electrodes with those of percutaneous placement, potentially improving treatment for chronic lower back pain patients.
NeuroOne estimates the current spinal cord stimulation market to be approximately $3 billion worldwide, citing large addressable patient populations with unmet clinical needs.
FAQ
What is the current stock price of NeuroOne Medical Technologies Corporation (NMTC)?
What is the market cap of NeuroOne Medical Technologies Corporation (NMTC)?
What does NeuroOne Medical Technologies Corporation focus on?
Where is NeuroOne Medical Technologies Corporation based?
What disorders does NeuroOne's technology address?
What is the Evo® sEEG system?
What are some of NeuroOne's current projects?
How can I contact NeuroOne Medical Technologies Corporation?
What recent financial updates has NeuroOne provided?
What type of medical technology does NeuroOne specialize in?
What is the significance of the FDA clearance for NeuroOne's technology?
Where can I find more detailed financial results and updates about NeuroOne?
